Systematic review of outcome measures following chemoradiotherapy for the treatment of anal cancer (CORMAC)
Open Access
- 22 March 2018
- journal article
- review article
- Published by Wiley in Colorectal Disease
- Vol. 20 (5) , 371-382
Abstract
Aim: Six Phase III randomized trials have determined the effectiveness of chemoradiotherapy as primary treatment for anal squamous cell carcinoma (ASCC), but outcomes reported in these trials varied widely, hindering evidence synthesis. To improve reporting in all future trials, we aim to develop a core outcomes set (COS). As the first stage of COS development, we undertook a systematic review to summarize the outcomes reported in studies evaluating chemoradiotherapy for ASCC.Method: Systematic literature searches identified studies evaluating radiotherapy or chemoradiotherapy for ASCC. Outcomes and accompanying definitions were extracted verbatim and categorized into domains.Results: From 5170 abstracts, we identified 95 eligible studies, reporting 1192 outcomes and 533 unique terms. We collapsed these terms into 86 standardized outcomes and five domains: survival; disease activity; life impact [including quality of life (QoL)]; delivery of care; and toxicity. The most commonly reported domains were survival and disease activity, reported in 74 (86%) and 54 (62%) studies, respectively. No outcome was reported in every publication. Over half (43/86) of the standardized outcome terms were reported in fewer than five studies, and 21 (25%) were reported in a single study only. There was wide variation in definitions of disease‐free survival, colostomy‐free survival and progression‐free survival (PFS). Anal continence was reported in only 35 (41%) studies.Conclusion: Outcomes reported in studies evaluating chemoradiotherapy for ASCC were heterogenous and definitions varied widely. Outcomes likely to be important to patients, such as ano‐rectal function, toxicity and QoL, have been neglected. A COS for future trials will address these issues.Keywords
Funding Information
- National Institute for Health Research
- Research for Patient Benefit Programme (PB-PG-1013-32064)
This publication has 61 references indexed in Scilit:
- Outcome of salvage surgery for anal squamous cell carcinomaColorectal Disease, 2013
- Induction Chemotherapy and Dose Intensification of the Radiation Boost in Locally Advanced Anal Canal Carcinoma: Final Analysis of the Randomized UNICANCER ACCORD 03 TrialJournal of Clinical Oncology, 2012
- Quality of life and tumor control after short split-course chemoradiation for anal canal carcinomaRadiation Oncology, 2010
- Overall Survival: Still the Gold StandardThe Cancer Journal, 2009
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009
- Evaluation of Planned Treatment Breaks During Radiation Therapy for Anal Cancer: Update of RTOG 92-08International Journal of Radiation Oncology - Biology - Physics (IJROBP), 2008
- Survival End Point Reporting in Randomized Cancer Clinical Trials: A Review of Major JournalsJournal of Clinical Oncology, 2008
- Anal Canal Carcinoma: Experience from a Single Korean InstitutionYonsei Medical Journal, 2007
- Role of Dose Intensity in Conservative Treatment ofAnal Canal CarcinomaOncology, 1998
- Epidermoid anal cancer: results from the UKCCCR randomised trial of radiotherapy alone versus radiotherapy, 5-fluorouracil, and mitomycinThe Lancet, 1996